{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:32:56Z","timestamp":1792513976704,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jhep.2019.05.017","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T08:42:49Z","timestamp":1560501769000},"page":"453-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB \u2013 Is one NUC better than the other?"],"prefix":"10.1016","volume":"71","author":[{"given":"Grace Lai-Hung","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.05.017_b0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.05.017_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2019.05.017_b0015","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.05.017_b0020","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2015.06.006","article-title":"The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study","volume":"63","author":"Lampertico","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.05.017_b0025","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.05.017_b0030","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/apt.14497","article-title":"Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B","volume":"47","author":"Wong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.05.017_b0035","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea","volume":"71","author":"Kim","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.05.017_b0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2019.05.017_b0045","unstructured":"Website: https:\/\/www.medpagetoday.com\/gastroenterology\/hepatitis\/79448?xid=nl_mpt_SRGastroenterology_2019-04-28&eun=g1111486d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=GastroUpdate_042819&utm_term=NL_Spec_Gastroenterology_Update_Active. Accessed on 30 April 2019."},{"key":"10.1016\/j.jhep.2019.05.017_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30227-0","article-title":"Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.05.017_b0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/EDE.0000000000000504","article-title":"Brief report: negative controls to detect selection bias and measurement bias in epidemiologic studies","volume":"27","author":"Arnold","year":"2016","journal-title":"Epidemiology."},{"key":"10.1016\/j.jhep.2019.05.017_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30259-2","article-title":"Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S Cohort","volume":"70","author":"Gordon","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.05.017_b0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12902","article-title":"Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients","volume":"48","author":"Koike","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2019.05.017_b0070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.05.017_b0075","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2019.05.017_b0080","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00262-010-0831-3","article-title":"Antitumor activity of type I and type III interferons in BNL hepatoma model","volume":"59","author":"Abushahba","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhep.2019.05.017_b0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamaoncol.2018.4039","article-title":"Tenofovir vs entecavir for hepatocellular carcinoma prevention in patients with chronic hepatitis B: one of these things is not like the other","volume":"5","author":"Flemming","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T15:17:14Z","timestamp":1566487034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819303034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0168827819303034"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.05.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB \u2013 Is one NUC better than the other?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.03.028","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}